Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Vaccination of patients with cutaneous melanoma with telomerase-specific peptides

doi: 10.1007/s00262-011-1061-z

Figure Lengend Snippet: Patients’ characteristics, T cell response, and survival time: (A) Two peptides (p540 and GV1001) and GM-CSF group, (B) One peptide (GV1001) and PPD23 group

Article Snippet: The telomerase peptide vaccines GV1001 (also called p611) and p540 were provided by GemVax AS, Porsgrunn, Norway.

Techniques: Injection, Proliferation Assay, Cytotoxicity Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Vaccination of patients with cutaneous melanoma with telomerase-specific peptides

doi: 10.1007/s00262-011-1061-z

Figure Lengend Snippet: Specific CTL responses against the vaccine peptides p540 and GV1001 in patient #4. a Pentamer staining of PBMCs before, i.e., at baseline, (upper panel) and after (lower panel) vaccination. The two right graphs represent staining with the HLA-A2/hTERT (p540) pentamers and the left graphs depict staining with HLA-A2/Tax pentamers (control). Cells were also stained for CD8. b Specific killing of T2 target cells pulsed either with p540 or a mixture of 8 different, overlapping nonapeptides covering the whole GV1001 amino acid sequence. Effector cells in this assay were harvested following the 4th, 6th, and 10th vaccinations and expanded by two cycles of in vitro stimulation by p540 and GV1001 peptides. Standard chromium release assay. T2 without peptide served as a negative control. c Dose–response curve for p540-specific CTL lysis by effector cells obtained from the blood sample harvested at week 6 and expanded as a cell line by additional rounds of peptide stimulation in vitro. d Cytotoxicity of the same cell line tested with p540-pulsed or unpulsed melanoma cell lines FM48 (HLA-A2 neg.) or FM3 (HLA-A2 pos.)

Article Snippet: The telomerase peptide vaccines GV1001 (also called p611) and p540 were provided by GemVax AS, Porsgrunn, Norway.

Techniques: Staining, Control, Sequencing, In Vitro, Release Assay, Negative Control, Lysis

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Vaccination of patients with cutaneous melanoma with telomerase-specific peptides

doi: 10.1007/s00262-011-1061-z

Figure Lengend Snippet: Analysis of CTL activity and proliferative responses of TLCs from patient #7. a Specific lysis of either unpulsed or p540-pulsed T2 cells and autologous PHA blasts. b Proliferative responses (cpm) of the indicated TLCs using T2 and PBMCs as APCs with or without peptide (p540). c Proliferative response of TLC #7 using PBMCs from different donors as APCs. The patient was HLA A2/A23 (B7/5703/C7) positive and the other donors shared A2 or A23 with the patient. d Proliferative response of TLC #6 (CD8+) and #127 (double negative) to different peptide concentrations. e Proliferative responses of 2 TLCs against recombinant hTERT and GV1001. The TLCs were incubated with APCs and the indicated concentrations of either recombinant hTERT or GV1001. cpm was measured in a standard 3-day proliferation assay used for TLCs

Article Snippet: The telomerase peptide vaccines GV1001 (also called p611) and p540 were provided by GemVax AS, Porsgrunn, Norway.

Techniques: Activity Assay, Lysis, Recombinant, Incubation, Proliferation Assay